Naloxone and rimonabant reduce the reinforcing properties of exercise in rats

Experimental and Clinical Psychopharmacology

Volumn 19, Issue 6, 2011, Pages 389-400

  Rasmussen, Erin B ^a   Hillman, Conrad ^a  

^a IDAHO STATE UNIVERSITY   (United States)

Author keywords

Exercise; Naloxone; Obese Zucker; Rimonabant; Wheel running reinforcement

Indexed keywords

NALOXONE; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; EXERCISE; FEMALE; LONG EVANS RAT; MOTIVATION; NONHUMAN; OBESITY; RAT; RAT STRAIN; REINFORCEMENT; REWARD; TASK PERFORMANCE; TREADMILL; ZUCKER RAT;

ANIMALS; CANNABINOIDS; EXTINCTION, PSYCHOLOGICAL; FEMALE; NALOXONE; NARCOTIC ANTAGONISTS; PHYSICAL CONDITIONING, ANIMAL; PIPERIDINES; PYRAZOLES; RATS; RATS, ZUCKER; REINFORCEMENT (PSYCHOLOGY);

EID: 83755219977     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/a0024142     Document Type: Article

References (84)

1. Agustín-Pavón C., Martínez-Ricós J., Martínez-García F., Lanuza E. Sex versus sweet: Opposite effects of opioid drugs on the reward of sucrose and sexual pheromones. Brain Research 1989, 492:15-18.
2. Banerji M.A., Tiewala M. Rimonabant-the RIO North America trial: A new strategy to sustaining weight loss and related morbidity. Current Diabetes Reports 2006, 6:228-229.
3. Batki S.L., Dimmock J.A., Wade M., Gately P.W., Cornell M., Maisto S.A., Ploutz-Snyder R. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. The American Journal on Addictions 2007, 16:253-259.
4. Beardsley P.M., Thomas B.F. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behavioural Pharmacology 2005, 16:275-296.
5. Beardsley P.M., Thomas B.F., McMahon L.R. Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. International Review of Psychiatry 2009, 2:134-142.
6. Belke T.W. The effect of a change in body weight on running and responding reinforced by the opportunity to run. The Psychological Record 1996, 36:421-433.
7. Belke T.W., Christie-Fougere M.M. Investigations of timing during the schedule and reinforcement intervals with wheel-running reinforcement. Behavioural Processes 2006, 73:240-247.
8. Belke T.W., Pierce W.D., Jensen K. Effect of short-term prefeeding and body weight on wheel running and responding reinforced by the opportunity to run in a wheel. Behavioural Processes 2004, 67:1-10.
9. Belke T.W. Responding for sucrose and wheel-running reinforcement: Effect of body weight manipulation. Behavioural Processes 2004, 65:189-199.
10. Boer D.P., Epling W.F., Pierce W.D., Russell J.C. Suppression of food deprivation- induced high-rate wheel running in rats. Physiology and Behavior 1990, 48:339-342.
11. Brown R.A., Abrantes A.M., Read J.P., Marcus B.H., Jakicic J., Strong D.R., Gordonh A. Aerobic exercise for alcohol recovery: Rationale, program description, and preliminary findings. Behavior Modification 2009, 33:220-249.
12. Brown R.A., Abrantes A.M., Read J.P., Marcus B.H., Jakicic J., Strong D.R., Gordon A. A pilot study of aerobic exercise as an adjunctive treatment for drug dependence. Mental Health and Physical Activity 2010, 3:27-34.
13. Caille S., Parsons L.H. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology 2006, 31:804-813.
14. Carroll M.E., Cosgrove K.P., Campbell U.C., Morgan A.D., Mickelberg J.L. Reductions in ethanol, phencyclidine, and food-maintained behavior by naltrexone pretreatment in monkeys is enhanced by open economic conditions. Psychopharmacology (Berlin) 2000, 148:412-422.
15. Cohen C., Kodas E., Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacology, Biochemistry and Behavior 2005, 81:387-395.
16. Cohen C., Perrault G., Griebel G., Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: Reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 2005, 30:145-155.
17. Cohen C., Perrault G., Voltz C., Steinberg R., Soubrie P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behavioural Pharmacology 2002, 13:451-463.
18. Collier G., Hirsch E. Reinforcing properties of spontaneous activity in the rat. Journal of Comparative Physiology A. Sensory, Neural, and Behavioral Physiology 1971, 77:155-160.
19. Connally R.E. Instrumental conditioning of the running-wheel response of food-deprived rats. Psychonomic Science 1969, 14:131-133.
20. Cooper Z.D., Comer S.D. Actions of drugs pertinent to their abuse: Targeting subjective, discriminative, and reinforcing effects for evaluation of potential substance-use therapies. Pharmacology and treatment of substance abuse: Evidence- and outcome-based perspectives 2009, 25-40. Routledge/Taylor & Francis Group, New York. L.M. Cohen, F. Collins, A. Young, D.E. McChargue, T.R. Leffingwell, K. Cook (Eds.).
21. Costello C.G. Depression: Loss of reinforcers or loss of reinforcer effectiveness?. Behavior Therapy 1972, 3:240-247.
22. Daniel M., Martin A.D., Carter J. Opiate receptor blockade by naltrexone and mood state after acute physical activity. British Journal of Sports Medicine 1992, 26:111-115.
23. Davidson D., Palfai T., Bird C., Swift R. Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcoholism, Clinical and Experimental Research 1999, 23:195-203.
24. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine 2005, 353:2121-2134.
25. De Vries T.J., Schoffelmeer A.N. Cannabinoid CB1 receptors control conditioned drug seeking. Trends in Pharmacological Sciences 2005, 26:420-426.
26. Dews P. Studies on behavior. I. Differential sensitivity to pentobarbital of pecking performance in pigeons depending on the schedule of reward. Journal of Pharmacology and Experimental Therapeutics 1955, 113:393-401.
27. Dubreucq S., Koehl M., Abrous D.N., Marsicano G., Chaouloff F. CB1 receptor deficiency decreases wheel-running activity: Consequences on emotional behaviours and hippocampal neurogenesis. Experimental Neurology 2010, 224:106-113.
28. Eikelboom R., Mills R. A microanalysis of wheel running in male and female rats. Physiology & Behavior 1988, 43:625-630.
29. Escher T., Mittleman G. Schedule-induced alcohol drinking: Non-selective effects of acamprosate and naltrexone. Addiction Biology 2006, 11:55-63.
30. Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant) 2008, European Medicines Agency, doi: Retrieved from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500014779.pdf.
31. Everson E.S., Daley A.J., Ussher M. The effects of moderate and vigorous exercise on desire to smoke, withdrawal symptoms and mood in abstaining young adult smokers. Mental Health and Physical Activity 2008, 1:26-31.
32. Forget B., Barthelemy S., Saurini F., Hamon M., Thiebot M.H. Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats. Psychopharmacology (Berlin) 2006, 189:59-69.
33. Forget B., Hamon M., Thiebot M.H. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology (Berlin) 2005, 181:722-734.
34. Galloway G.P., Koch M., Cello R., Smith D.E. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: An open-label trial. BMC Psychiatry 2005, 5:1-10.
35. Glass M.J., O'Hare E., Cleary J.P., Billington C.J., Levine A.S. The effect of naloxone on food-motivated behavior in the obese Zucker rat. Psychopharmacology 1999, 141:378-384.
36. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berlin) 1997, 129:99-111.
37. Higgins S.T., Heil S.H., Lussier J.P. Clinical implications of reinforcement as a determinant of substance use disorders. Annual Review of Psychology 2004, 55:431-461.
38. Hill M.N., Titterness A.K., Morrish A.C., Carrier E.J., Lee T.T., Gil-Mohapel J., Christie B.R. Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus. Hippocampus 2010, 20:513-523.
39. Iversen I.H. Techniques for establishing schedules with wheel running as reinforcement in rats. Journal of the Experimental Analysis of Behavior 1993, 60:219. 218.
40. Järvekülg A., Viru A. Opioid receptor blockade eliminates mood effects of aerobic gymnastics. International Journal of Sports Medicine 2002, 23:155-157.
41. Kagan J., Brekun M. The reward value of running activity. Journal of Comparative Physiology A. Sensory, Neural, and Behavioral Physiology 1953, 47:108.
42. Kamdar N.K., Miller S.A., Syed Y.M., Bhayana R., Gupta T., Rhodes J.S. Acute effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice. Psychopharmacology (Berlin) 2007, 192:207-217.
43. Keeney B.K., Raichlen D.A., Meek T.H., Wijeratne R.S., Middleton K.M., Gerdeman G.L., Garland T. Differential response to a selective cannabinoid receptor antagonist (SR141716: Rimonabant) in female mice from lines selectively bred for high voluntary wheel-running behaviour. Behavioural Pharmacology 2008, 19:812-820.
44. Kirkham T.C., Williams C.M. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology 2001, 153:267-270.
45. Kodas E., Cohen C., Louis C., Griebel G. Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. Psychopharmacology (Berlin) 2007, 194:161-171.
46. Le Foll B., Forget B., Aubin H.J., Goldberg S.R. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: Insights from pre-clinical and clinical studies. Addiction Biology 2008, 13:239-252.
47. Le Foll B., Goldberg S.R. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. Journal of Pharmacology and Experimental Therapeutics 2005, 312:875-883.
48. Mark T.L., Kranzler H.R., Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug and Alcohol Dependence 2003, 71:219-228.
49. Markou A., Weiss F., Gold L., Caine B., Schulteis G., Koob G. Animal models of drug craving. Psychopharmacology 1993, 112:163-182.
50. Navarro M., Carrera M.R., Del Arco I., Trigo J.M., Koob G.F., Rodriguez de Fonseca F. Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats. European Journal of Pharmacology 2004, 501:235-237.
51. Orman J.S., Keating G.M. Buprenorphine/naloxone: A review of its use in the treatment of opioid dependence. Drugs 2009, 69:577-607.
52. Orman J.S., Keating G.M. Spotlight on buprenorphine/naloxone in the treatment of opioid dependence. CNS Drugs 2009, 23:899-902.
53. Pierce W., Epling D., Frank W., Boer D.P. Deprivation and satiation: The interrelations between food and wheel running. Journal of the Experimental Analysis of Behavior 1986, 46:199-210.
54. Pillolla G., Melis M., Perra S., Muntoni A.L., Gessa G.L., Pistis M. Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo. Psychopharmacology (Berlin) 2007, 191:843-853.
55. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. Journal of the American Medical Association 2006, 295:761-775.
56. Prochaska J.J., Hall S.M.H., Muňoz R.F., Reus V., Hu D. Physical activity as a strategy for maintaining tobacco abstinence: A randomized trial. Preventive Medicine: An International Journal Devoted to Practice and Theory 2008, 47:215-220.
57. Rasmussen E.B., Huskinson S.L. Effects of rimonabant on behavior maintained by progressive ratio schedules of sucrose reinforcement in obese Zucker (fa/fa) rats. Behavioural Pharmacology 2008, 19:735-742.
58. Rasmussen E.B., Reilly W., Hillman C. Demand for sucrose reinforcement in lean and obese Zucker rats. Behavioural Processes 2010, 85:191-197.
59. Roberts D., Bennett S. Heroin self-administration in rats under a progressive ratio schedule. Psychopharmacology (Berlin) 1993, 111:215-218.
60. Ross S., Peselow E. Pharmacotherapy of addictive disorders. Neuropharmacology 2009, 32:277-289.
61. Samson H.H., Doyle T. Oral ethanol self-administration in the rat: Effect of naloxone. Pharmacology, Biochemistry, and Behavior 1985, 22:91-99.
62. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006, 368:1660-1672.
63. Schneider M., Heise V., Spanagel R. Differential involvement of the opioid receptor antagonist naloxone in motivational and hedonic aspects of reward. Behavioural Brain Research 2000, 117:163-171.
64. Schull J., Walker J., Fitzgerald K., Hiilivirta L. Effects of sex, thyro-parathyroidectomy, and light regime on levels and circadian rhythms of wheel-running in rats. Physiology & Behavior 1989, 46:341-346.
65. Schwartz-Stevens K., Files F., Samson H.H. Effects of morphine and naloxone on ethanol and sucrose-reinforced responding in nondeprived rats. Alcoholism: Clinical and Experimental Research 1992, 16:822-832.
66. Sharpe A.L., Samson H.H. Effect of naloxone on appetitive and consummatory phases of ethanol self-administration. Alcoholism: Clinical and Experimental Research 2001, 25:1006-1011.
67. Sisti H.M., Lewis M.J. Naloxone suppression and morphine enhancement of voluntary wheel-running activity in rats. Pharmacology, Biochemistry, and Behavior 2001, 70:359-365.
68. Smith S., Rasmussen E.B. Effects of 2-AG on the reinforcing properties of wheel activity in obese and lean Zucker rats. Behavioural Pharmacology 2010, 21:292-300.
69. Solinas M., Goldberg S. Motivational effects of cannabinoids and opioids on food reinforcement depend on simutaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology 2005, 30:2025-2035.
70. Spanagel R., Herz A., Bals-Kubik R., Shippenberg T. β-endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens. Psychopharmacology 1991, 104:51-56.
71. Sparling P.B., Giuffrida A., Piomelli D., Rosskopf L., Dietrich A. Exercise activates the endocannabinoid system. Neuroreport 2003, 14:2209-2211.
72. Stafford D., LeSage M.G., Glowa J.R. Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: A review. Psychopharmacology 1998, 139:169. 164.
73. Stitzer M., Petry N. Contingency management for treatment of substance abuse. Annual Review of Clinical Psychology 2006, 2:411-434.
74. Sullivan M.A., Vosburg S.K., Comer S.D. Depot naltrexone: Antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berlin) 2006, 189:37-46.
75. Tokuyama K., Saito M., Okuda H. Effects of wheel running on food intake and weight gain of male and female rats. Physiology & Behavior 1982, 28:899-903.
76. Trujillo K., Belluzzi J., Stein L. Effects of opiate antagonists and their quaternary analogues on nucleus accumbens self-stimulation. Behavioural Brain Research 1989, 33:181-188.
77. Trujillo K., Belluzzi J., Stein L. Opiate antagonists and self-stimulation: Extinction-like response patterns suggest selective reward deficit. Behavioural Brain Research 1989, 492:15-28.
78. Testimony before FDA Advisory Committee of rimonabant (HRG Publication #1815) 2007, United States Food and Drug Administration, Retrieved from: http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4306oph1-01-Wolfe.pdf.
79. Vlachou S., Nomikos G.G., Panagis G. Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. Psychopharmacology (Berlin) 2006, 188:293-305.
80. Wakley A.A., Rasmussen E.B. Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats. Pharmacology, Biochemistry and Behavior 2009, 94:30-36.
81. Walker B.M., Koob G.F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 2008, 33:643-652.
82. Weinstock J., Barry D., Petry N.M. Exercise-related activities are associated with positive outcome in contingency management treatment for substance use disorders. Addictive Behaviors 2008, 33:1072-1075.
83. Williams K.L., Broadbridge C.L. Potency of naltrexone to reduce ethanol self-administration in rats is greater for subcutaneous versus intraperitoneal injection. Alcohol 2009, 43:119-126.
84. Zurita A., Martijena I., Cuadra G., Brandão M., Molina V. Early exposure to chronic variable stress facilitates the occurrence of anhedonia and enhanced emotional reactions to novel stressors: Reversal by naltrexone pretreatment. Behavioural Brain Research 2010, 208:466-472.